Trump Administration Considers Houman Hemmati for FDA Vaccine Leadership

The Trump administration is reportedly considering Houman Hemmati, an ophthalmologist and entrepreneur, for the position of director at the FDA's Center for Biologics Evaluation and Research (CBER). This information comes from multiple sources familiar with internal discussions, as reported by both The Washington Post and Reuters. Hemmati is known for his appearances on Fox News, which adds to his public profile.

Reuters

The potential appointment follows the announcement that the current CBER director, Vinay Prasad, will be leaving the agency at the end of the month. Prasad, who is an oncologist, has been a controversial figure due to his critical stance on U.S. drug and vaccine policies, particularly regarding COVID-19 mandates. His tenure was marked by significant disputes over vaccine approvals, including those for Moderna's COVID-19 vaccine and various gene therapies.

Reuters

Andrew Nixon, a spokesperson for the Department of Health and Human Services, stated, "No decision has been made on the selection of the next CBER director. We continue to vet highly qualified candidates." This indicates that while Hemmati is under consideration, the selection process is ongoing and not yet finalized.

Reuters

Hemmati's potential appointment has raised concerns among some health policy experts and public health advocates. Critics argue that his background and affiliations may not align with the rigorous scientific standards expected of the FDA's leadership, especially in light of Prasad's contentious tenure. The implications of appointing someone with a less traditional background in vaccine regulation could lead to further scrutiny of the FDA's decision-making processes.

Reuters

As the Trump administration continues to evaluate candidates for the CBER director position, the public and health professionals will be watching closely. The selection of Hemmati, if confirmed, could signal a shift in the FDA's approach to vaccine regulation and public health policy, particularly in the context of ongoing debates surrounding vaccine safety and efficacy.

Reuters

• “No decision has been made on the selection of the next CBER director. We continue to vet highly qualified candidates,” — Andrew Nixon, HHS Spokesperson

Reuters